About sonoma pharmaceuticals - SNOA
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. Its products are used for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
SNOA At a Glance
Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court
Boulder, Colorado 80301
| Phone | 1-800-759-9305 | Revenue | 19.53M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,175,000.00 | |
| Sector | Health Technology | 2026 Sales Growth | 36.681% | |
| Fiscal Year-end | 03 / 2027 | Employees | 259 | |
| View SEC Filings |
SNOA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.184 |
| Price to Book Ratio | 1.238 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.874 |
| Enterprise Value to Sales | 0.104 |
| Total Debt to Enterprise Value | 0.415 |
SNOA Efficiency
| Revenue/Employee | 75,401.544 |
| Income Per Employee | -12,258.687 |
| Receivables Turnover | 7.728 |
| Total Asset Turnover | 1.402 |
SNOA Liquidity
| Current Ratio | 2.486 |
| Quick Ratio | 1.731 |
| Cash Ratio | 0.496 |
SNOA Profitability
| Gross Margin | 37.969 |
| Operating Margin | -12.602 |
| Pretax Margin | -17.507 |
| Net Margin | -16.258 |
| Return on Assets | -22.788 |
| Return on Equity | -84.599 |
| Return on Total Capital | -80.645 |
| Return on Invested Capital | -79.355 |
SNOA Capital Structure
| Total Debt to Total Equity | 27.205 |
| Total Debt to Total Capital | 21.387 |
| Total Debt to Total Assets | 5.984 |
| Long-Term Debt to Equity | 15.153 |
| Long-Term Debt to Total Capital | 11.913 |